Most-cited articles · 2024
The 100 most-cited articles in International Journal of Radiation Oncology*Biology*Physics, 2024
Ranked by OpenAlex citation count on 29 October 2026, out of 2,889 eligible articles International Journal of Radiation Oncology*Biology*Physics published in 2024. Ranks are frozen; this page will not change. Number one, with 91 citations: Proton FLASH: Impact of Dose Rate and Split Dose on Acute Skin Toxicity in a Murine Model.
- Cohort
- 2,889 articles
- Listed
- Top 100 (3.5%)
- Open access
- 65 of 100
- Snapshot
- 2026-10-29
The most-cited articles from International Journal of Radiation Oncology*Biology*Physics in 2024 cluster around several themes. FLASH radiation therapy features prominently, with studies examining dose rate effects, normal tissue sparing, and mechanisms in preclinical models. Clinical trials in lung cancer, head and neck cancer, and prostate cancer also rank highly, as do technical reports on stereotactic and proton therapy. The top paper is "Proton FLASH: Impact of Dose Rate and Split Dose on Acute Skin Toxicity in a Murine Model" by Sørensen and colleagues, with 91 citations.
Readers can use this list to identify the studies that attracted the most attention in the citation record for the year. It reflects a mix of preclinical FLASH research, randomized clinical trial results, and technical or consensus reports. The ranking is based on OpenAlex citation counts among 2889 eligible articles and offers a neutral snapshot of which topics and publications drew the most subsequent references.
Introduction written from the titles and abstracts on this list. Every figure below is the source.
Ask about these papers
Grounded in this list only, with sources.
- 1top 0.1%
Proton FLASH: Impact of Dose Rate and Split Dose on Acute Skin Toxicity in a Murine Model
Brita Singers Sørensen, Eleni Kanouta, Christina Ankjærgaard, Line Kristensen, Jacob Johansen and 4 more
91 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.04.071OpenAlex
Show abstractHide abstract
PURPOSE: Preclinical studies have shown a preferential normal tissue sparing effect of FLASH radiation therapy with ultra-high dose rates. The aim of the present study was to use a murine model of acute skin toxicity to investigate the biologic effect of varying dose rates, time structure, and introducing pauses in the dose delivery. METHODS AND MATERIALS: The right hind limbs of nonanaesthetized mice were irradiated in the entrance plateau of a pencil beam scanning proton beam with 39.3 Gy. Experiment 1 was with varying field dose rates (0.7-80 Gy/s) without repainting, experiment 2 was with varying field dose rates (0.37-80 Gy/s) with repainting, and in experiment 3, the dose was split into 2, 3, 4, or 6 identical deliveries with 2-minute pauses. In total, 320 mice were included, with 6 to 25 mice per group. The endpoints were skin toxicity of different levels up to 25 days after irradiation. RESULTS: , which is the dose rate to induce a response in 50% of the animals, depended on the level of skin toxicity, with the higher toxicity levels displaying a FLASH effect at 0.7-2 Gy/s.…
- 2top 0.1%
Interim Futility Results of NRG-HN005, A Randomized, Phase II/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients
Sue Sun Yom, J. Harris, Jimmy J. Caudell, Jessica Lyn Geiger, John N. Waldron and 15 more
76 citationsdoi:10.1016/j.ijrobp.2024.08.014OpenAlex
- 3top 0.2%
Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)
Meredith Giuliani, Édith Filion, Sérgio Luis Faria, Vijayananda Kundapur, Thi Trinh Thuc Vu and 16 more
65 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.03.050OpenAlex
Show abstractHide abstract
PURPOSE: The use of stereotactic body radiation therapy for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (NCT03306680) aimed to determine the maximally tolerated dose of stereotactic body radiation therapy for ultracentral non-small cell lung carcinoma, using a time-to-event continual reassessment methodology. METHODS AND MATERIALS: Patients with T1-3N0M0 (≤6 cm) non-small cell lung carcinoma were eligible. The maximally tolerated dose was defined as the dose of radiation therapy associated with a ≤30% rate of grade (G) 3 to 5 prespecified treatment-related toxicity occurring within 2 years of treatment. The starting dose level was 60 Gy in 8 daily fractions. The dose-maximum hotspot was limited to 120% and within the planning tumor volume; tumors with endobronchial invasion were excluded. This primary analysis occurred 2 years after completion of accrual. RESULTS: Between March 2018 and April 2021, 30 patients were enrolled at 5 institutions. The median age was 73 years (range, 65-87) and 17 (57%) were…
- 4top 0.2%
Redefining FLASH RT: the impact of mean dose rate and dose per pulse in the gastrointestinal tract
Kevin Liu, Trey Waldrop, Edgardo A Aguilar, Nefetiti Mims, Denae W. Neill and 9 more
62 citationsOpen accessdoi:10.1016/j.ijrobp.2024.10.009OpenAlex
- 5top 0.2%
Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005
Kyndra S. Higgins, Chengping Hu, Helen J. Ross, S.K. Jabbour, David Kozono and 10 more
56 citationsOpen accessdoi:10.1016/j.ijrobp.2024.08.013OpenAlex
- 6top 0.3%
FLASH Proton Radiation Therapy Mitigates Inflammatory and Fibrotic Pathways and Preserves Cardiac Function in a Preclinical Mouse Model of Radiation-Induced Heart Disease
Kyle Kim, Michele M. Kim, Giorgos Skoufos, Eric S. Diffenderfer, Seyyedeh Azar Oliaei Motlagh and 13 more
55 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.01.224OpenAlex
Show abstractHide abstract
PURPOSE: Studies during the past 9 years suggest that delivering radiation at dose rates exceeding 40 Gy/s, known as "FLASH" radiation therapy, enhances the therapeutic index of radiation therapy (RT) by decreasing normal tissue damage while maintaining tumor response compared with conventional (or standard) RT. This study demonstrates the cardioprotective benefits of FLASH proton RT (F-PRT) compared with standard (conventional) proton RT (S-PRT), as evidenced by reduced acute and chronic cardiac toxicities. METHODS AND MATERIALS: Mice were imaged using cone beam computed tomography to precisely determine the heart's apex as the beam isocenter. Irradiation was conducted using a shoot-through technique with a 5-mm diameter circular collimator. Bulk RNA-sequencing was performed on nonirradiated samples, as well as apexes treated with F-PRT or S-PRT, at 2 weeks after a single 40 Gy dose. Inflammatory responses were assessed through multiplex cytokine/chemokine microbead assay and immunofluorescence analyses. Levels of perivascular fibrosis were quantified using Masson's Trichrome and…
- 7top 0.3%
Acute Hypoxia Does Not Alter Tumor Sensitivity to FLASH Radiation Therapy
Ron Leavitt, Aymeric Almeida, Veljko Grilj, Pierre Montay‐Gruel, Céline Godfroid and 4 more
51 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.02.015OpenAlex
Show abstractHide abstract
PURPOSE: Tumor hypoxia is a major cause of treatment resistance, especially to radiation therapy at conventional dose rate (CONV), and we wanted to assess whether hypoxia does alter tumor sensitivity to FLASH. METHODS AND MATERIALS: We engrafted several tumor types (glioblastoma [GBM], head and neck cancer, and lung adenocarcinoma) subcutaneously in mice to provide a reliable and rigorous way to modulate oxygen supply via vascular clamping or carbogen breathing. We irradiated tumors using a single 20-Gy fraction at either CONV or FLASH, measured oxygen tension, monitored tumor growth, and sampled tumors for bulk RNAseq and pimonidazole analysis. Next, we inhibited glycolysis with trametinib in GBM tumors to enhance FLASH efficacy. RESULTS: Using various subcutaneous tumor models, and in contrast to CONV, FLASH retained antitumor efficacy under acute hypoxia. These findings show that in addition to normal tissue sparing, FLASH could overcome hypoxia-mediated tumor resistance. Follow-up molecular analysis using RNAseq profiling uncovered a FLASH-specific profile in human GBM that…
- 8top 0.3%
Minibeam Radiation Therapy Treatment (MBRT): Commissioning and First Clinical Implementation
Michael P. Grams, Chrystian Quintero Mateus, Maryam Mashayekhi, Robert W. Mutter, Valentin Djonov and 12 more
48 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.06.035OpenAlex
Show abstractHide abstract
PURPOSE: Minibeam radiation therapy (MBRT) is characterized by the delivery of submillimeter-wide regions of high "peak" and low "valley" doses throughout a tumor. Preclinical studies have long shown the promise of this technique, and we report here the first clinical implementation of MBRT. METHODS AND MATERIALS: A clinical orthovoltage unit was commissioned for MBRT patient treatments using 3-, 4-, 5-, 8-, and 10-cm diameter cones. The 180 kVp output was spatially separated into minibeams using a tungsten collimator with 0.5 mm wide slits spaced 1.1 mm on center. Percentage depth dose (PDD) measurements were obtained using film dosimetry and plastic water for both peak and valley doses. PDDs were measured on the central axis for offsets of 0, 0.5, and 1 cm. The peak-to-valley ratio was calculated at each depth for all cones and offsets. To mitigate the effects of patient motion on delivered dose, patient-specific 3-dimensional-printed collimator holders were created. These conformed to the unique anatomy of each patient and affixed the tungsten collimator directly to the body. Two…
- 9top 0.4%
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial
Devin D. Schellenberg, Zsolt Gabos, Adele Duimering, Brock John Debenham, Alysa M. Fairchild and 25 more
46 citationsdoi:10.1016/j.ijrobp.2024.08.031OpenAlex
- 10top 0.4%
NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy
Harald Paganetti, Charles B. Simone, Walter R. Bosch, Daphne Adele Haas-Kogan, David G. Kirsch and 9 more
45 citationsOpen accessdoi:10.1016/j.ijrobp.2024.07.2152OpenAlex
- 11top 0.4%
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Amy J. Wisdom, Christopher Andrew Barker, Joe Yujiao Chang, Sandra Demaria, Silvia Chiara Formenti and 11 more
38 citationsdoi:10.1016/j.ijrobp.2023.12.046OpenAlex
- 12top 0.5%
A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
Mariana Poppe, Jennifer G. Le‐Rademacher, B. G. Haffty, Eric K. Hansen, Jay Agarwal and 15 more
36 citationsdoi:10.1016/j.ijrobp.2024.07.002OpenAlex
- 13top 0.5%
Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial
Gerard Walls, Hitesh B. Mistry, Fabrice Barlési, Andrea Bezjak, Cecile Le Pechoux and 4 more
35 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.02.063OpenAlex
Show abstractHide abstract
PURPOSE: CONVERT was a phase 3 international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5-year outcomes of these regimens delivered with conformal techniques. METHODS AND MATERIALS: CONVERT (NCT00433563) randomized patients 1:1 between OD RT (66 Gy/33 fractions/6.5 weeks) and BD RT (45 Gy/30 fractions/3 weeks), both delivered with concurrent cisplatin/etoposide. Three-dimensional conformal RT was mandatory, intensity-modulated RT was permitted, and elective nodal irradiation was not allowed. Prophylactic cranial irradiation was delivered at the discretion of treating clinicians. RT treatment planning was subject to central quality assurance. RESULTS: Five hundred forty-seven patients were recruited at 73 centers. The median follow-up for the surviving cohort (n = 164) was 81.2 months. The median survival for the OD and BD arms were 25.4 months (95% CI, 21.1-30.9) and 30.0 months (95% CI, 25.3-36.5; hazard ratio, 1.13; 95% CI, 0.92-1.38; P = .247). Performance status and tumor volume were…
- 14top 0.5%
Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer
J.A. Efstathiou, B.Y. Yeap, J.M. Michalski, Nora Horick, Anthony Laurence Zietman and 15 more
34 citationsdoi:10.1016/j.ijrobp.2024.08.012OpenAlex
- 15top 0.6%
A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Jiayi Huang, Jian Li Campian, Todd A. DeWees, Zdeněk Škrott, Martin Mistrík and 14 more
34 citationsOpen accessdoi:10.1016/j.ijrobp.2024.05.009OpenAlex
- 16top 0.6%
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
Lisa Francesca Licitra, Makoto Tahara, Kevin Joseph Harrington, M. Olivera Hurtado de Mendoza, Yi Guo and 15 more
34 citationsdoi:10.1016/j.ijrobp.2024.01.016OpenAlex
- 17top 0.6%
Whole Abdominal Pencil Beam Scanned Proton FLASH Increases Acute Lethality
Brett I. Bell, Christian Velten, Michael Pennock, Minglei Kang, Kathryn E. Tanaka and 17 more
33 citationsOpen accessdoi:10.1016/j.ijrobp.2024.09.006OpenAlex
- 18top 0.7%
PTCOG Ocular Statement: Expert Summary of Current Practices and Future Developments in Ocular Proton Therapy
Jan Hrbáček, Andrzej Kacperek, Jan-Willem M. Beenakker, Linda Mortimer, A. Denker and 6 more
33 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.06.017OpenAlex
Show abstractHide abstract
Although rare cancers, ocular tumors are a threat to vision, quality of life, and potentially life expectancy of a patient. Ocular proton therapy (OPT) is a powerful tool for successfully treating this disease. The Particle Therapy Co-Operative Ocular Group) formulated an Evidence and Expert-Based Executive Summary of Current Practices and Future Developments in OPT: comparative dosimetric and clinical analysis with the different OPT systems is essential to set up planning guidelines, implement best practices, and establish benchmarks for eye preservation, vision, and quality of life measures. Contemporary prospective trials in select subsets of patients (eg, tumors near the optic disc and/or macula) may allow for dosimetric and clinical analysis between different radiation modalities and beamline systems to evaluate differences in radiation delivery and penumbra, and resultant tumor control, normal tissue complication rates, and overall clinical cost-effectiveness. To date, the combination of multimodal imaging (fundus photography, ultrasound, etc), ophthalmologist assessment, and…
- 19top 0.7%
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas
Leila T. Tchelebi, Diana Segovia, Koren S. Smith, Qian Shi, Thomas J. FitzGerald and 9 more
33 citationsOpen accessdoi:10.1016/j.ijrobp.2024.03.013OpenAlex
- 20top 0.7%
Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chong Han, Jingping Qiu, Lu Bai, Tingting Liu, Jun Chen and 2 more
33 citationsdoi:10.1016/j.ijrobp.2024.01.217OpenAlex
- 21top 0.8%
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial
Sarah J. Derby, Mark R. Jackson, Karin Williams, Jamie Stobo, Caroline Kelly and 9 more
33 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.01.011OpenAlex
Show abstractHide abstract
PURPOSE: Patients with glioblastoma who are older or have poor performance status (PS) experience particularly poor clinical outcomes. At the time of study initiation, these patients were treated with short-course radiation therapy (40 Gy in 15 fractions). Olaparib is an oral inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) that is well tolerated as a single agent but exacerbates acute radiation toxicity in extracranial sites. Preclinical data predicted that PARP inhibitors would enhance radiosensitivity in glioblastoma without exacerbating adverse effects on the normal brain. METHODS AND MATERIALS: Phase 1 of the PARADIGM trial was a 3+3 dose-escalation study testing olaparib in combination with radiation therapy (40 Gy 15 fractions) in patients with newly diagnosed glioblastoma who were unsuitable for radical treatment either because they were aged 70 years or older (World Health Organization PS 0-1) or aged 18 to 69 years with PS 2. The primary outcome was the recommended phase 2 dose of olaparib. Secondary endpoints included safety and tolerability, overall…
- 22top 0.8%
Probiotic Consortia Protect the Intestine Against Radiation Injury by Improving Intestinal Epithelial Homeostasis
Liwei Xie, Haiyan Lu, Lin-Feng Tang, Feng‐Ling Tang, Rui-Qiu Zhu and 4 more
32 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.03.003OpenAlex
Show abstractHide abstract
PURPOSE: Radiation-induced intestinal injury (RIII) commonly occur during abdominal-pelvic cancer radiation therapy; however, no effective prophylactic or therapeutic agents are available to manage RIII currently. This study aimed to clarify the potential of probiotic consortium supplementation in alleviating RIII. METHODS AND MATERIALS: Male C57BL/6J mice were orally administered a probiotic mixture comprising Bifidobacterium longum BL21, Lactobacillus paracasei LC86, and Lactobacillus plantarum Lp90 for 30 days before exposure to 13 Gy of whole abdominal irradiation. The survival rates, clinical scores, and histologic changes in the intestines of mice were assessed. The impacts of probiotic consortium treatment on intestinal stem cell proliferation, differentiation, and epithelial barrier function; oxidative stress; and inflammatory cytokines were evaluated. A comprehensive examination of the gut microbiota composition was conducted through 16S rRNA sequencing, while changes in metabolites were identified using liquid chromatography-mass spectrometry. RESULTS: The probiotic…
- 23top 0.8%
Diagnostic CT-Enabled Planning (DART): Results of a Randomized Trial in Palliative Radiation Therapy
Melissa O’Neil, Joanna M. Laba, Timothy K. Nguyen, Michael I. Lock, Christopher D. Goodman and 9 more
31 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.03.005OpenAlex
Show abstractHide abstract
PURPOSE: Using diagnostic computed tomography (dCT) scans instead of CT simulation (CTsim) scans can increase departmental efficiency and reduce patient burden. The goal of the DART trial was to assess the efficacy and acceptability of dCT-based planning workflows with a focus on patient experiences, plan deliverability and adequacy of target coverage, and workflows. METHODS AND MATERIALS: Patients undergoing same-day CTsim and treatment for palliative radiation therapy to thoracic, abdominopelvic, or proximal limb targets with a recent dCT (within 28 days) in a reproducible position were eligible. After stratifying by target type (bone or soft tissue vs. visceral), participants were randomized (1:2 ratio) between CTsim-based (CTsim arm) vs. dCT-based planning (dCT arm). The primary endpoint was time in center (TIC), defined as total time spent in the cancer center on first day of treatment, from first radiation department appointment to first fraction completion. Secondary endpoints included plan deliverability, adequacy of target coverage, and stakeholder acceptability. RESULTS:…
- 24top 0.9%
Quality and Safety Considerations for Adaptive Radiation Therapy: An ASTRO White Paper
Indrin J. Chetty, Bin Cai, Michael David Chuong, Samantha L. Dawes, William Adrian Hall and 8 more
28 citationsdoi:10.1016/j.ijrobp.2024.10.011OpenAlex
- 25top 0.9%
Toward Clinical-Grade Evaluation of Large Language Models
Amy Catherine Moreno, Danielle S. Bitterman
28 citationsOpen accessdoi:10.1016/j.ijrobp.2023.11.012OpenAlex
- 26top 0.9%
A Phase 2 Randomized Clinical Trial Evaluating 4-Dimensional Computed Tomography Ventilation-Based Functional Lung Avoidance Radiation Therapy for Non-Small Cell Lung Cancer
Andrew M. Baschnagel, Mattison J. Flakus, Eric M. Wallat, Antonia E. Wuschner, Richard J. Chappell and 6 more
28 citationsOpen accessdoi:10.1016/j.ijrobp.2024.02.019OpenAlex
- 27top 1%
NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy
Nina Niu Sanford, Amol Kumar Narang, Todd Anthony Aguilera, Michael Frederick Bassetti, Michael David Chuong and 17 more
27 citationsOpen access (OTHER-OA)doi:10.1016/j.ijrobp.2024.10.026OpenAlex
- 28top 1%
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial
Jay Paul Reddy, Alexander Dean Sherry, Bryan M. Fellman, Suyu Liu, Tharakeswara Kumar Bathala and 19 more
27 citationsOpen accessdoi:10.1016/j.ijrobp.2024.10.030OpenAlex
- 29top 1.1%
Oxygen Enhancement Ratio-Weighted Dose Quantitatively Describes Acute Skin Toxicity Variations in Mice After Pencil Beam Scanning Proton FLASH Irradiation With Changing Doses and Time Structures
Per Rugaard Poulsen, Jacob Johansen, Mateusz Krzysztof Sitarz, Eleni Kanouta, Line Kristensen and 2 more
27 citationsdoi:10.1016/j.ijrobp.2024.02.050OpenAlex
- 30top 1.1%
Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review
Saurav Verma, Sympascho Young, Gabriel Boldt, Phillip Blanchette, Michael I. Lock and 2 more
27 citationsdoi:10.1016/j.ijrobp.2024.01.001OpenAlex
- 31top 1.1%
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR
Juliette Thariat, M. Bosset, Antoine Falcoz, Déwi Vernerey, Y. Pointreau and 25 more
26 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.084OpenAlex
Show abstractHide abstract
PURPOSE: Patients with oligometastasis may have prolonged survival with multisite stereotactic ablative radiation therapy (SABR). Evidence to support this paradigm is scarce in squamous cell carcinoma of the head and neck (HNSCC). The multicenter open-label randomized GORTEC 2014-04 (NCT03070366) phase 2 study assesses survival without definitive quality of life (QoL) deterioration of omitting upfront chemotherapy in oligometastatic patients with HNSCC using SABR alone, in the French Head and Neck Intergroup. METHODS AND MATERIALS: Eligible participants (≥18 years old with 1-3 oligometastases, the Eastern Cooperative Oncology Group score 0-2) were randomly assigned (1:1) to receive chemo-SABR or SABR alone. Salvage treatments were left to the physician's appreciation. The standard therapy was considered to be systemic therapy and SABR (chemo-SABR; EXTREME regimen [5 fluorouracil/platinum/cetuximab]). The primary endpoint was 1-year (±3 months) overall survival rate without definitive deterioration (ie, without subsequent better QoL score) of the global European Organisation for…
- 32top 1.2%
Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy
Daniel Y. Song, Mateusz Dabkowski, Paulo Costa, Rizwan Nurani, Michael Kos and 11 more
26 citationsdoi:10.1016/j.ijrobp.2024.07.2145OpenAlex
- 33top 1.2%
Auto-delineation of Treatment Target Volume for Radiation Therapy Using Large Language Model-Aided Multimodal Learning
Praveenbalaji Rajendran, Yizheng Chen, Liang Qiu, Thomas Niedermayr, Wu Liu and 9 more
25 citationsOpen accessdoi:10.1016/j.ijrobp.2024.07.2149OpenAlex
- 34top 1.2%
Early Disease Recurrence Following Post-operative HPV ctDNA Directed Active Surveillance in Oropharyngeal Carcinoma – Outcomes of a Prospective Pilot Study
L. Chen, Marc A. Cohen, Vaios Hatzoglou, Z. Zhang, Nadeem Riaz and 15 more
25 citationsdoi:10.1016/j.ijrobp.2024.02.003OpenAlex
- 35top 1.3%
Differential Remodeling of the Oxylipin Pool After FLASH Versus Conventional Dose-Rate Irradiation In Vitro and In Vivo
Lucie Portier, Patricia Daira, Baptiste Fourmaux, Sophie Heinrich, Margaux Becerra and 7 more
25 citationsdoi:10.1016/j.ijrobp.2024.01.210OpenAlex
- 36top 1.3%
Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care
Thilo Schuler, Stephanie Roderick, Shelley Wong, Alannah Kejda, Kylie Grimberg and 16 more
24 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.09.041OpenAlex
Show abstractHide abstract
PURPOSE: The feasibility of simulation-free radiation therapy (SFRT) has been demonstrated but information regarding its routine care impact and scalability is lacking. METHODS AND MATERIALS: In this single-institution, retrospective cohort study, all patients receiving palliative radiation therapy at an Australian tertiary cancer center were eligible for consideration of SFRT unless mask immobilization, a stereotactic technique, or a definitive dose was indicated. Coprimary endpoints were SFRT utilization, impact on consultation-to-RT time, and on-couch treatment duration. Timing metrics were compared with a contemporary local cohort that received simulation-based palliative radiation therapy using unadjusted Wilcoxon rank-sum tests and a propensity score-matched regression. Electronic patient-reported outcomes captured 2-week toxicity and pain response. RESULTS: Between April 2018 and February 2024, 2849 palliative radiation courses were delivered, of which 1904 were eligible. Of the 1904 courses, 1000 (52.5% SFRT utilization) received SFRT, including 668 using intensity-modulated…
- 37top 1.3%
Clinical Results and Prognostic Factors in Boron Neutron Capture Therapy for Recurrent Squamous Cell Carcinoma of the Head and Neck Under the Japan National Health Insurance System: A Retrospective Study of the Initial 47 Patients
Katsumi Hirose, Mariko Sato
24 citationsOpen accessdoi:10.1016/j.ijrobp.2024.03.041OpenAlex
- 38top 1.4%
A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy
Juanita Mary Crook, Nikitha Moideen, Greg Arbour, Felipe Castro, Cynthia Araujo and 8 more
24 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.02.064OpenAlex
Show abstractHide abstract
PURPOSE: To compare health-related quality of life (QoL) in urinary, bowel, and sexual domains after combined external beam radiation therapy (EBRT) and either low-dose rate (LDR) or high-dose rate (HDR) prostate brachytherapy (BT). METHODS AND MATERIALS: Eligible men with intermediate or high-risk prostate cancer treated with combined pelvic EBRT and BT were randomly assigned to either HDR (15 Gy) or LDR (110 Gy) boost. International Prostate Symptom Score, Index of Erectile Function, and Expanded Prostate Cancer Composite were collected at baseline, 1, 3, 6, and 12 months, every 6 months to 3 years and then annually along with prostate-specific antigen/testosterone. Fisher's exact test compared categorical variables and the Mann-Whitney U test Expanded Prostate Cancer Index Composite (EPIC) domain scores. RESULTS: From January 2014 to December 2019, a random number generator assigned 195 men: 108 to HDR and 87 to LDR. Median age was 71 years. Risk group was high in 57% and unfavorable intermediate in 43%. Androgen deprivation (used in 74%) began with 3 months neoadjuvant and…
- 39top 1.4%
Multi-Institutional Audit of FLASH and Conventional Dosimetry With a 3D Printed Anatomically Realistic Mouse Phantom
Muhammad Ramish Ashraf, Stavros Melemenidis, Kevin Liu, Veljko Grilj, Jeannette Jansen and 20 more
24 citationsOpen accessdoi:10.1016/j.ijrobp.2024.03.017OpenAlex
- 40top 1.4%
Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost
Allison Y. Zhong, Asona J. Lui, Svetlana Kuznetsova, Karoline Kallis, Christopher C. Conlin and 12 more
24 citationsOpen accessdoi:10.1016/j.ijrobp.2024.06.007OpenAlex
- 41top 1.5%
Refining Treatment Planning in STereotactic Arrhythmia Radioablation: Benchmark Results and Consensus Statement From the STOPSTORM.eu Consortium
Valeria Trojani, Melanie Grehn, Andrea Botti, Brian V. Balgobind, A. Savini and 25 more
23 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2331OpenAlex
Show abstractHide abstract
PURPOSE: STereotactic Arrhythmia Radioablation (STAR) showed promising results in patients with refractory ventricular tachycardia. However, clinical data are scarce and heterogeneous. The STOPSTORM.eu consortium was established to investigate and harmonize STAR in Europe. The primary goal of this benchmark study was to investigate current treatment planning practice within the STOPSTORM project as a baseline for future harmonization. METHODS AND MATERIALS: Planning target volumes (PTVs) overlapping extracardiac organs-at-risk and/or cardiac substructures were generated for 3 STAR cases. Participating centers were asked to create single-fraction treatment plans with 25 Gy dose prescriptions based on in-house clinical practice. All treatment plans were reviewed by an expert panel and quantitative crowd knowledge-based analysis was performed with independent software using descriptive statistics for International Commission on Radiation Units and Measurements report 91 relevant parameters and crowd dose-volume histograms. Thereafter, treatment planning consensus statements were…
- 42top 1.5%
The Effect of Radiation Treatment of Solid Tumors on Neutrophil Infiltration and Function: A Systematic Review
Léon Raymakers, Thijs J. Demmers, Gert J. Meijer, Izaak Quintus Molenaar, Hjalmar C. van Santvoort and 4 more
23 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2141OpenAlex
Show abstractHide abstract
Radiation therapy (RT) initiates a local and systemic immune response which can induce antitumor immunity and improve immunotherapy efficacy. Neutrophils are among the first immune cells that infiltrate tumors after RT and are suggested to be essential for the initial antitumor immune response. However, neutrophils in tumors are associated with poor outcomes and RT-induced neutrophil infiltration could also change the composition of the tumor microenvironment (TME) in favor of tumor progression. To improve RT efficacy for patients with cancer it is important to understand the interplay between RT and neutrophils. Here, we review the literature on how RT affects the infiltration and function of neutrophils in the TME of solid tumors, using both patients studies and preclinical murine in vivo models. In general, it was found that neutrophil levels increase and reach maximal levels in the first days after RT and can remain elevated up to 3 weeks. Most studies report an immunosuppressive role of neutrophils in the TME after RT, caused by upregulated expression of neutrophil indoleamine…
- 43top 1.5%
Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial
Binnaz Yasar, Yae‐Eun Suh, Ewan Chapman, Luke Nicholls, Daniel Henderson and 9 more
23 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.03.009OpenAlex
Show abstractHide abstract
PURPOSE: Dose-escalated radiation therapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiation therapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease while limiting toxicity. This study evaluated the toxicity and quality of life (QoL) with CyberKnife-based SBRT and simultaneous integrated boost in localized prostate cancer. METHODS AND MATERIALS: Eligible participants included newly diagnosed, biopsy-proven unfavorable intermediate- to high-risk localized prostate cancer (at least 1 of the following: Gleason ≥4+3, magnetic resonance imaging(MRI)-defined T3a N0, prostate-specific antigen ≥20) with up to 2 MRI-identified DILs. Participants received 36.25 Gy in 5 fractions on alternative days with a simultaneous boost to DIL up to 47.5 Gy as allowed by organ-at-risk constraints delivered by CyberKnife. All participants received androgen deprivation therapy. The primary outcome measure was acute grade 2+ genitourinary toxicity. Acute and late…
- 44top 1.6%
Thoracic Proton Minibeam Radiation Therapy: Tissue Preservation and Survival Advantage Over Conventional Proton Therapy
Annaïg Bertho, Ramón Ortiz, Mathieu Maurin, Marjorie Juchaux, Cristèle Gilbert and 6 more
22 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.04.011OpenAlex
Show abstractHide abstract
PURPOSE: Proton minibeam radiation therapy (pMBRT) is an innovative radiation therapy approach that highly modulates the spatial dimension of the dose delivery using narrow, parallel, and submillimetric proton beamlets. pMBRT has proven its remarkable healthy tissue preservation in the brain and skin. This study assesses the potential advantages of pMBRT for thoracic irradiations compared with conventional radiation therapy in terms of normal tissue toxicity. The challenge here was the influence of respiratory motion on the typical peak and valley dose patterns of pMBRT and its potential biologic effect. METHODS AND MATERIALS: The whole thorax of naïve C57BL/6 mice received one fraction of high dose (18 Gy) pMBRT or conventional proton therapy (CPT) without any respiratory control. The development of radiation-induced pulmonary fibrosis was longitudinally monitored using cone beam computed tomography. Anatomopathologic analysis was carried out at 9 months postirradiation and focused on the reaction of the lungs' parenchyma and the response of cell types involved in the development…
- 45top 1.6%
Incorporation of Functional Lung Imaging Into Radiation Therapy Planning in Patients With Lung Cancer: A Systematic Review and Meta-Analysis
Julie Midroni, Rohan Salunkhe, Zhihui Liu, Ronald Chow, Gabriel Boldt and 4 more
22 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.04.001OpenAlex
Show abstractHide abstract
Our purpose was to provide an understanding of current functional lung imaging (FLI) techniques and their potential to improve dosimetry and outcomes for patients with lung cancer receiving radiation therapy (RT). Excerpta Medica dataBASE (EMBASE), PubMed, and Cochrane Library were searched from 1990 until April 2023. Articles were included if they reported on FLI in one of: techniques, incorporation into RT planning for lung cancer, or quantification of RT-related outcomes for patients with lung cancer. Studies involving all RT modalities, including stereotactic body RT and particle therapy, were included. Meta-analyses were conducted to investigate differences in dose-function parameters between anatomic and functional RT planning techniques, as well as to investigate correlations of dose-function parameters with grade 2+ radiation pneumonitis (RP). One hundred seventy-eight studies were included in the narrative synthesis. We report on FLI modalities, dose-response quantification, functional lung (FL) definitions, FL avoidance techniques, and correlations between FL irradiation…
- 46top 1.6%
Brain and Brain Stem Necrosis After Reirradiation for Recurrent Childhood Primary Central Nervous System Tumors: A PENTEC Comprehensive Review
Thankamma Ajithkumar, Michele Avanzo, Ellen D. Yorke, Derek S. Tsang, Michael T. Milano and 11 more
22 citationsdoi:10.1016/j.ijrobp.2023.12.043OpenAlex
- 47top 1.7%
Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy
Julian Philipp Layer, Ehab Shiban, Stefanie Brehmer, Christian Diehl, Douglas Guedes de Castro and 14 more
22 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.01.009OpenAlex
Show abstractHide abstract
PURPOSE: After surgical resection of brain metastases (BMs), intraoperative radiation therapy (IORT) provides a promising alternative to adjuvant external beam radiation therapy by enabling superior organ-at-risk preservation, reduction of in-hospital times, and timely admission to subsequent systemic treatments, which increasingly comprise novel targeted immunotherapeutic approaches. We sought to assess the safety and efficacy of IORT in combination with immune checkpoint inhibitors (ICIs) and other targeted therapies (TTs). METHODS AND MATERIALS: In a multicentric approach incorporating individual patient data from 6 international IORT centers, all patients with BMs undergoing IORT were retrospectively assessed for combinatorial treatment with ICIs/TTs and evaluated for toxicity and cumulative rates, including wound dehiscence, radiation necrosis, leptomeningeal spread, local control, distant brain progression (DBP), and estimated overall survival. RESULTS: In total, 103 lesions with a median diameter of 34 mm receiving IORT combined with immunomodulatory systemic treatment or…
- 48top 1.7%
Characterization of a Time-Resolved, Real-Time Scintillation Dosimetry System for Ultra-High Dose-Rate Radiation Therapy Applications
Alexander Baikalov, Daline Tho, Kevin Liu, Stefan H. Bartzsch, Sam A. Beddar and 1 more
21 citationsOpen accessdoi:10.1016/j.ijrobp.2024.11.092OpenAlex
- 49top 1.7%
FLASH Bragg-Peak Irradiation With a Therapeutic Carbon Ion Beam: First In Vivo Results
Walter Tinganelli, Anggraeini Puspitasari-Kokko, Olga Sokol, Alexander Helm, Palma Simoniello and 14 more
21 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.089OpenAlex
Show abstractHide abstract
PURPOSE: In recent years, ultra-high dose rate (UHDR) irradiation has emerged as a promising innovative approach to cancer treatment. Characteristic feature of this regimen, commonly referred to as FLASH effect, demonstrated primarily for electrons, photons, or protons, is the improved normal tissue sparing, whereas the tumor control is similar to the one of the conventional dose-rate (CDR) treatments. The FLASH mechanism is, however, unknown. One major question is whether this effect is maintained when using densely ionizing (high-LET) heavy nuclei. METHODS MATERIALS: C beam using an osteosarcoma mouse model. RESULTS: We show that UHDR irradiation was less toxic in the normal tissue compared with CDR while maintaining tumor control. The immune activation was also comparable in UHDR and CDR groups. Both UHDR and CDR exposures steered the metagenome toward a balanced state. CONCLUSIONS: These results suggest that the UHDR irradiations can improve the safety and effectiveness of heavy ion therapy, and provide a crucial benchmark for current mechanistic FLASH models. However,…
- 50top 1.8%
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial
Gabriella Macchia, Maura Campitelli, Donato Pezzulla, Simona Lucci, Andrei Fodor and 25 more
21 citationsdoi:10.1016/j.ijrobp.2024.09.036OpenAlex
- 51top 1.8%
Artificial Intelligence-Empowered Multistep Integrated Radiation Therapy Workflow for Nasopharyngeal Carcinoma
Yu‐Xian Yang, Xin Yang, Xiaobo Jiang, Lin Li, Guangyu Wang and 25 more
20 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.096OpenAlex
Show abstractHide abstract
PURPOSE: To establish an artificial intelligence (AI)-empowered multistep integrated (MSI) radiation therapy (RT) workflow for patients with nasopharyngeal carcinoma (NPC) and evaluate its feasibility and clinical performance. METHODS AND MATERIALS: Patients with NPC scheduled for MSI RT workflow were prospectively enrolled. This workflow integrates RT procedures from computed tomography (CT) scan to beam delivery, all performed with the patient on the treatment couch. Workflow performance, tumor response, patient-reported acute toxicities, and quality of life were evaluated. RESULTS: From March 2022 to October 2023, 120 newly diagnosed, nonmetastatic patients with NPC were enrolled. Of these, 117 completed the workflow with a median duration of 23.2 minutes (range, 16.3-45.8). Median translation errors were 0.2 mm (from CT scan to planning approval) and 0.1 mm (during beam delivery). AI-generated contours required minimal revision for the high-risk clinical target volume and organs at risk, minor revision for the involved cervical lymph nodes and low-risk clinical target volume…
- 52top 1.8%
Discordance in Acute Gastrointestinal Toxicity between Synchrotron-Based Proton and Linac-based Electron Ultra-High Dose Rate Irradiation
Kevin Liu, U Titt, Nolan Esplen, Luke Connell, Elise Konradsson and 10 more
20 citationsOpen accessdoi:10.1016/j.ijrobp.2025.01.007OpenAlex
- 53top 1.9%
Intracellular Oxygen Transient Quantification in Vivo During Ultra-High Dose Rate FLASH Radiation Therapy
Arthur F. Pétusseau, Megan Clark, Petr Brůža, David J. Gladstone, Brian W. Pogue
20 citationsOpen accessdoi:10.1016/j.ijrobp.2024.04.068OpenAlex
- 54top 1.9%
Vestibular Schwannoma International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS Study
Othman Bin-Alamer, Hussam Abou‐Al‐Shaar, Selçuk Peker, Yavuz Samancı, Isabelle Pelcher and 25 more
20 citationsdoi:10.1016/j.ijrobp.2024.04.004OpenAlex
- 55top 2%
Cluster-Based Toxicity Estimation of Osteoradionecrosis Via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification
Seyedmohammadhossein Hosseinian, Mehdi Hemmati, Cem Dede, Travis C. Salzillo, Lisanne Vania van Dijk and 4 more
20 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.02.021OpenAlex
Show abstractHide abstract
PURPOSE: Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference by exploiting structural properties of data and provide a clinically reliable model for ORN risk evaluation through an unsupervised-learning analysis that incorporates the whole radiation dose distribution on the mandible. METHODS AND MATERIALS: The analysis was conducted on retrospective data of 1259 patients with head and neck cancer treated at The University of Texas MD Anderson Cancer Center between 2005 and 2015. During a minimum 12-month posttherapy follow-up period, 173 patients in this cohort (13.7%) developed ORN (grades I to IV). The (structural) clusters of mandibular dose-volume histograms (DVHs) for these patients were identified using the K-means clustering method. A soft-margin support vector machine was used to determine the cluster borders and partition the dose-volume space. The risk of ORN for each dose-volume region was calculated based on incidence rates…
- 56top 2%
Patient-Specific Deep Learning Tracking Framework for Real-Time 2D Target Localization in Magnetic Resonance Imaging-Guided Radiation Therapy
Elia Lombardo, Laura Velezmoro, Sebastian Norbert Marschner, Moritz Rabe, Claudia Tejero and 8 more
19 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.10.021OpenAlex
Show abstractHide abstract
Purpose We propose a tumor tracking framework for 2D cine magnetic resonance imaging (MRI) based on a pair of deep learning (DL) models relying on patient-specific (PS) training. Methods and Materials The chosen DL models are: (1) an image registration transformer and (2) an auto-segmentation convolutional neural network (CNN). We collected over 1,400,000 cine MRI frames from 219 patients treated on a 0.35 T MRI-linac plus 7500 frames from additional 35 patients that were manually labeled and subdivided into fine-tuning, validation, and testing sets. The transformer was first trained on the unlabeled data (without segmentations). We then continued training (with segmentations) either on the fine-tuning set or for PS models based on 8 randomly selected frames from the first 5 seconds of each patient's cine MRI. The PS auto-segmentation CNN was trained from scratch with the same 8 frames for each patient, without pre-training. Furthermore, we implemented B-spline image registration as a conventional model, as well as different baselines. Output segmentations of all models were…
- 57top 2%
A Novel Dose Rate Optimization Method to Maximize Ultrahigh-Dose-Rate Coverage of Critical Organs at Risk Without Compromising Dosimetry Metrics in Proton Pencil Beam Scanning FLASH Radiation Therapy
Xingyi Zhao, Sheng Huang, Haibo Lin, J. Isabelle Choi, Kun Zhu and 3 more
19 citationsdoi:10.1016/j.ijrobp.2024.06.002OpenAlex
- 58top 2.1%
Reduced Risk of Severe Radiation-Induced Lymphopenia in Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer: A Comparative Analysis of Carbon Versus Photon Therapy
Gowoon Yang, Woong Sub Koom, Byung Min Lee, Tetsuro Isozaki, Makoto Shinoto and 2 more
19 citationsdoi:10.1016/j.ijrobp.2024.04.003OpenAlex
- 59top 2.1%
A Pilot Study of Simulation-Free Hippocampal-Avoidance Whole Brain Radiation Therapy Using Diagnostic MRI-Based and Online Adaptive Planning
Kylie H. Kang, Alex T. Price, Francisco J. Reynoso, Eric Laugeman, Eric D. Morris and 8 more
19 citationsdoi:10.1016/j.ijrobp.2024.03.039OpenAlex
- 60top 2.1%
OTUB1 Targets CHK1 for Deubiquitination and Stabilization to Facilitate Lung Cancer Progression and Radioresistance
Juanjuan Wang, Yuting Liu, Di Wu, Chen Tian, Jiaqi Gao and 8 more
19 citationsdoi:10.1016/j.ijrobp.2024.01.202OpenAlex
- 61top 2.2%
Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma
André Tsin Chih Chen, Alexandre Ruggieri Serante, Aline Sgnolf Ayres, Juliana Ono Tonaki, Raquel Moreno and 13 more
19 citationsdoi:10.1016/j.ijrobp.2024.01.013OpenAlex
- 62top 2.2%
A Study on Breast Cancer Patient Care Using Chatbot and Video Education for Radiation Therapy: A Randomized Controlled Trial
Junbok Lee, Hwa Kyung Byun, Yong Tae Kim, Jaeyong Shin, Yong Bae Kim
18 citationsdoi:10.1016/j.ijrobp.2024.12.012OpenAlex
- 63top 2.2%
Association Between the Regular Use of Vaginal Dilators and/or Sexual Activity and Vaginal Morbidity in Locally Advanced Cervical Cancer Survivors: An EMBRACE-I Study Report
Kathrin Kirchheiner, Alexandru Zaharie, Stéphanie Smet, Sofia Spampinato, Cyrus Chargari and 15 more
18 citationsOpen access (OTHER-OA)doi:10.1016/j.ijrobp.2024.09.011OpenAlex
- 64top 2.3%
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial
Rachel Glicksman, Srinivas Raman, Xiang Y. Ye, Philippe Lucien Bedard, Scott Victor Bratman and 11 more
18 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.09.002OpenAlex
Show abstractHide abstract
PURPOSE: In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing on a background of stable or responding to widespread cancer. Although the standard of care for OP is changing systemic therapy (ST), stereotactic body radiation therapy (SBRT) is being explored as an alternative local therapy targeting the sites of progression. METHODS AND MATERIALS: RADIANT (NCT04122469) was a single-center phase 2 study of patients with metastatic genitourinary (GU), breast, and gastrointestinal (GI) cancers, receiving ST for ≥3 months, with radiographic OP disease in ≤5 sites. Patients received SBRT for all OP disease in 1 to 5 fractions and were maintained on ST. The primary endpoint was the cumulative incidence of change in ST, which was estimated using the Aalen-Johansen method. Secondary endpoints included progression-free survival (PFS) and overall survival estimated using the Kaplan-Meier method, as well as toxicity and health-related quality of life. Comparisons between diagnosis groups were done using the log-rank test. A 2-sided p value <.05 was…
- 65top 2.3%
Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease
Timothy K. Nguyen, Sherif Ramadan, David A. Palma, Mark Thomas Corkum, Melissa O’Neil and 10 more
18 citationsdoi:10.1016/j.ijrobp.2024.06.033OpenAlex
- 66top 2.3%
Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma
Quan Wang, Xiaoquan Ji, Jing Sun, Aimin Zhang, Jun Hua Jia and 3 more
18 citationsdoi:10.1016/j.ijrobp.2024.03.035OpenAlex
- 67top 2.4%
USP11 Exacerbates Radiation-Induced Pneumonitis by Activating Endothelial Cell Inflammatory Response via OTUD5-STING Signaling
Yiting Tang, Ting-Ya Wang, Liming Gu, Ying Xu, Yang Zhao and 5 more
18 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.01.220OpenAlex
Show abstractHide abstract
Purpose Radiation-induced pneumonitis (RIP) seriously limits the application of radiation therapy in the treatment of thoracic tumors, and its etiology and pathogenesis remain elusive. This study aimed to elucidate the role of ubiquitin-specific peptidase 11 (USP11) in the progression of RIP and the associated underlying mechanisms. Methods and Materials Changes in cytokines and infiltrated immune cells were detected by enzyme-linked immunosorbent assays and immunohistochemistry after exposure to 20 Gy x-ray with whole-thorax irradiation. The effects of USP11 expression on endothelial cell proliferation and apoptosis were analyzed by costaining of CD31/Ki67 and CD31/caspase-3 in vivo, and the production of cytokines and reactive oxygen species was confirmed by reverse-transcription polymerase chain reaction and flow cytometry in vitro . Comprehensive proteome and ubiquitinome analyses were used for USP11 substrate screening after radiation. Results were verified by Western blotting and coimmunoprecipitation experiments. Recombinant adeno-associated virus lung vectors expressing…
- 68top 2.4%
Deep Learning Auto-Segmentation Network for Pediatric Computed Tomography Data Sets: Can We Extrapolate From Adults?
Kartik Kumar, Adam Unjin Yeo, Lachlan McIntosh, Tomas Kron, Greg Wheeler and 1 more
18 citationsdoi:10.1016/j.ijrobp.2024.01.201OpenAlex
- 69top 2.4%
Radiation Therapy for Meningiomas – Where Do We Stand and What's on the Horizon?
Felix Ehret, Leon El Baya, Sara Erridge, Marc R. Bussière, Joost J.C. Verhoeff and 4 more
17 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.10.034OpenAlex
Show abstractHide abstract
Radiation therapy, including conventionally fractionated external beam radiation therapy, stereotactic radiosurgery, and fractionated stereotactic radiation therapy, is a cornerstone in the interdisciplinary management of meningiomas. Recent advances in radiation oncology and also in other fields, such as neuropathology and imaging, have various implications for meningioma radiation therapy. This review aims to summarize current and anticipated developments, as well as active clinical trials related to the use of radiation therapy for meningiomas. In imaging, positron emission tomography has proven valuable for assessing the spatial extension of meningiomas and may enhance target delineation, treatment response monitoring, and recurrence assessment after radiation therapy. Particle therapy, including protons and carbon ions, as well as stereotactic radiosurgery and fractionated stereotactic radiation therapy, allow for conformal treatments that permit dose escalation in selected patients with high-grade meningiomas. Additionally, emerging integrated molecular and genetic…
- 70top 2.5%
Stereotactic Radiation Therapy in 3 Fractions for T1 Glottic Cancer
Giuseppe Sanguineti, Pasqualina D’Urso, Marta Bottero, Alessia Farneti, Lucia Goanta and 2 more
17 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.09.051OpenAlex
Show abstractHide abstract
PURPOSE/OBJECTIVE(S): To report the results of a phases 1 and 2 study on stereotactic body radiation therapy (SBRT) for early glottic cancer. METHODS AND MATERIALS: This a prospective study at a single institution enrolling patients with T1 glottic cancer. The true vocal cords (TVCs) were divided into thirds and the third(s) containing disease prescribed 36 Gy in 3 fractions. The portions of the TVCs next to the involved one were planned to receive 30 Gy in 3 fxs. SBRT was delivered by a linear accelerator-based approach using multiple arcs. Toxicity was scored by Common Terminology Criteria for Adverse Events and late events were considered those occurring 3 months after SBRT. Voice quality was investigated by the Voice Handicap Index at regular intervals. The planned sample size was 75 patients. RESULTS: Accrual was discontinued after 33 patients because of concerns for late toxicity. T stage was as follows: T1a: 23 patients (69.7%); T1b: 10 patients (30.3%). All patients received the planned treatment and the median follow-up time was 51.5 months (IQR, 47.9-61.0 months). At last…
- 71top 2.5%
The Value and Safety of Adjuvant Radiation Therapy After Radical Cystectomy in Locally Advanced Urothelial Bladder Cancer: A Controlled Randomized Study
Mohamed S. Zaghloul, Ahmed Khaled Alnagmy, Hatem Aboul Kassem, Mohamed M. Abdel Hakim, Ahmed Abdallah and 3 more
17 citationsOpen accessdoi:10.1016/j.ijrobp.2024.05.012OpenAlex
- 72top 2.5%
A Hard Truth to Swallow: Critically Evaluating the MD Anderson Dysphagia Inventory (MDADI) as an Endpoint in Human Papillomavirus-associated Oropharyngeal Cancer Trials
Lachlan J. McDowell, Madeleine Trudy King, Katherine A. Hutcheson, Jolie G. Ringash, Sue Sun Yom and 4 more
17 citationsOpen access (OTHER-OA)doi:10.1016/j.ijrobp.2024.05.005OpenAlex
- 73top 2.6%
Deep Learning for Automatic Gross Tumor Volumes Contouring in Esophageal Cancer Based on Contrast-Enhanced Computed Tomography Images: A Multi-Institutional Study
Shuaitong Zhang, Kunwei Li, Yuchen Sun, Yun Wan, Yong Ao and 9 more
17 citationsdoi:10.1016/j.ijrobp.2024.02.035OpenAlex
- 74top 2.6%
Oxygen Consumption In Vivo by Ultra-High Dose Rate Electron Irradiation Depends Upon Baseline Tissue Oxygenation
Jacob P. Sunnerberg, Armin D. Tavakkoli, Arthur F. Pétusseau, Noah J. Daniel, Austin M. Sloop and 8 more
16 citationsOpen accessdoi:10.1016/j.ijrobp.2024.10.018OpenAlex
- 75top 2.6%
Proton Therapy for Spinal Tumors: A Consensus Statement From the Particle Therapy Cooperative Group
Arpit M. Chhabra, James William Snider III, Adam J. Kole, Markus Stock, Adam L. Holtzman and 13 more
16 citationsdoi:10.1016/j.ijrobp.2024.04.007OpenAlex
- 76top 2.7%
Three-Dimensional Deep Learning Normal Tissue Complication Probability Model to Predict Late Xerostomia in Patients With Head and Neck Cancer
Hung Chu, Suzanne P.M. de Vette, Hendrike Neh, Nanna Maria Sijtsema, Roel J.H.M. Steenbakkers and 5 more
16 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2334OpenAlex
Show abstractHide abstract
Purpose Conventional normal tissue complication probability (NTCP) models for patients with head and neck cancer are typically based on single-value variables, which, for radiation-induced xerostomia, are baseline xerostomia and mean salivary gland doses. This study aimed to improve the prediction of late xerostomia by using 3-dimensional information from radiation dose distributions, computed tomography imaging, organ-at-risk segmentations, and clinical variables with deep learning (DL). Methods and Materials An international cohort of 1208 patients with head and neck cancer from 2 institutes was used to train and twice validate DL models (deep convolutional neural network, EfficientNet-v2, and ResNet) with 3-dimensional dose distribution, computed tomography scan, organ-at-risk segmentations, baseline xerostomia score, sex, and age as input. The NTCP endpoint was moderate-to-severe xerostomia 12 months postradiation therapy. The DL models' prediction performance was compared with a reference model: a recently published xerostomia NTCP model that used baseline xerostomia score and…
- 77top 2.7%
Preoperative Magnetic Resonance Guided Single-Dose Partial Breast Irradiation: 5-Year Results of the Prospective Single-Arm ABLATIVE Trial
Yasmin A. Civil, Jeanine E. Vasmel, Ramona K. Charaghvandi, Anette C. Houweling, Celien P.H. Vreuls and 12 more
16 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2326OpenAlex
Show abstractHide abstract
PURPOSE: Preoperative partial breast irradiation (PBI) can increase accuracy of target volume definition and decrease irradiated volumes compared with postoperative PBI. In the ABLATIVE trial (NCT02316561), 15 of 36 patients achieved pathologic complete response 6 to 8 months after preoperative PBI and breast-conserving surgery (BCS). We now present the 5-year results. METHODS AND MATERIALS: The ABLATIVE trial is a Dutch prospective cohort study conducted in 4 hospitals. Women aged ≥50 years with unifocal, nonlobular breast cancer, estrogen receptor-positive, HER2-negative, and a tumor negative sentinel node were treated between 2015 and 2018 with preoperative single-dose PBI followed by BCS after 6 or 8 months. The primary endpoint was pathologic complete response. Secondary endpoints were annually evaluated oncological outcomes, toxicity, cosmetic outcome (assessed by patients and physicians), and quality of life. RESULTS: Thirty-six patients were treated with BCS 6 (n = 15) and 8 (n = 21) months following PBI. Median tumor size was 13 mm (IQR 9-16 mm). After a median follow-up of…
- 78top 2.7%
Clinical Implementation and Dosimetric Evaluation of a Robust Proton Lattice Planning Strategy Using Primary and Robust Complementary Beams
Sina Mossahebi, Jason K. Molitoris, Yannick P. Poirier, Jenna Jatczak, Baoshe Zhang and 4 more
16 citationsdoi:10.1016/j.ijrobp.2024.06.009OpenAlex
- 79top 2.8%
Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy
Sarah T. Arron, Javier Cañueto, Jennifer J. Siegel, Alison L. Fitzgerald, Anesh Prasai and 2 more
16 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.05.022OpenAlex
Show abstractHide abstract
PURPOSE: Adjuvant radiation therapy (ART) for cutaneous squamous cell carcinoma is recommended based on a number of wide-ranging clinicopathologic features, which encompass a broad array of patients. The 40-gene expression profile (GEP) test classifies cutaneous squamous cell carcinoma tumors into low (class 1), higher (class 2A), or highest (class 2B) risk of nodal and/or distant metastasis. This study's hypotheses are as follows: (1) local recurrence is associated with metastatic disease progression and (2) 40-GEP, by identifying high risk for metastasis, could predict a metastasis-specific benefit from ART. METHODS AND MATERIALS: Samples were obtained from 920 patients (ART-untreated: 496 class 1, 335 class 2A, and 33 class 2B; ART-treated: 11 class 1, 35 class 2A, and 10 class 2B) who were matched on clinical risk factors and stratified by ART status to create 49 matched patient strata. To control for the variety of characteristics and treatment selection bias, randomly sampled pairs of matched ART and non-ART patients comprising 10,000 resampled cohorts were each analyzed for…
- 80top 2.8%
Clinical Experience With an Offline Adaptive Radiation Therapy Head and Neck Program: Dosimetric Benefits and Opportunities for Patient Selection
Michalis Aristophanous, Eric Aliotta, Phillip Lichtenwalner, Shira Abraham, Mohammad Nehmeh and 12 more
16 citationsOpen accessdoi:10.1016/j.ijrobp.2024.02.016OpenAlex
- 81top 2.9%
The Association of Linear Energy Transfer and Dose With Radiation Necrosis After Pencil Beam Scanning Proton Therapy in Pediatric Posterior Fossa Tumors
Jarey H. Wang, Ryan T. Oglesby, Anh Tran, Melike Güryildirim, Mattea Miller and 5 more
15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.11.086OpenAlex
- 82top 2.9%
Generalizable Magnetic Resonance Imaging-based Nasopharyngeal Carcinoma Delineation: Bridging Gaps Across Multiple Centers and Raters With Active Learning
Xiangde Luo, Hongqiu Wang, Jinfeng Xu, Lu Li, Yue Zhao and 8 more
15 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.11.064OpenAlex
Show abstractHide abstract
PURPOSE: To develop a deep learning method exploiting active learning and source-free domain adaptation for gross tumor volume delineation in nasopharyngeal carcinoma (NPC), addressing the variability and inaccuracy when deploying segmentation models in multicenter and multirater settings. METHODS AND MATERIALS: One thousand fifty-seven magnetic resonance imaging scans of patients with NPC from 5 hospitals were retrospectively collected and annotated by experts from the same medical group with consensus for multicenter adaptation evaluation. One data set was used for model development (source domain), with the remaining 4 for adaptation testing (target domains). Meanwhile, another set of 170 patients with NPC, with annotations delineated by 4 independent experts, was created for multirater adaptation evaluation. We evaluated the pretrained model's migration ability to the 4 multicenter and 4 multirater target domains. Dice similarity coefficient (DSC), 95% Hausdorff distance (HD95), and other metrics were used for quantitative evaluations. RESULTS: In the adaptation of dataset5 to…
- 83top 2.9%
Assessment of Photon-Counting Computed Tomography for Quantitative Imaging in Radiation Therapy
Jens Zimmerman, Gavin G. Poludniowski
15 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.11.069OpenAlex
Show abstractHide abstract
PURPOSE: To test a first-generation clinical photon-counting computed tomography (PCCT) scanner's capabilities to characterize materials in an anthropomorphic head phantom for radiation therapy purposes. METHODS AND MATERIALS: A CIRS 731-HN head-and-neck phantom (CIRS/SunNuclear) was scanned on a NAEOTOM Alpha PCCT and a SOMATOM Definition AS+ with single-energy and dual-energy CT techniques (SECT and DECT, respectively), both scanners manufactured by Siemens (Siemens Healthineers). A method was developed to derive relative electron density (RED) and effective atomic number (EAN) from linear attenuation coefficients (LACs) of virtual mono-energetic images and applied for the PCCT and DECT data. For DECT, Siemens' syngo.via "Rho/Z"-algorithm was also used. Proton stopping-power ratios (SPRs) were calculated based on RED/EAN with the Bethe equation. For SECT, a stoichiometric calibration to SPR was used. Nine materials in the phantom were segmented, excluding border pixels. Distributions and root-mean-square deviations within the material regions were evaluated for LAC, RED/EAN, and…
- 84top 3%
Dynamics of Daily Glioblastoma Evolution During Chemoradiation Therapy on the 0.35T Magnetic Resonance Imaging-Linear Accelerator
Kaylie Cullison, Kayla Samimi, Jonathan B. Bell, Danilo Maziero, Alessandro Valderrama and 9 more
15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.09.028OpenAlex
- 85top 3%
Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial
Vedang Murthy, Priyamvada Maitre, Ganesh Bakshi, Mahendra Pal, Maneesh Singh and 16 more
15 citationsdoi:10.1016/j.ijrobp.2024.09.040OpenAlex
- 86top 3%
Safety and Preliminary Efficacy of AZD1390 + Radiation Therapy for Glioblastoma
J.T. Yang, Patrick Yung Wen, B.S. Imber, Jan Drappatz, R. Jena and 12 more
15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.07.217OpenAlex
- 87top 3.1%
PSMAddition: Phase 3 Trial of [177lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. Soc Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Hyun Kim, S.T. Tagawa, Oliver A. Sartor, Fred Saad C, Ashley L. Reid and 4 more
15 citationsdoi:10.1016/j.ijrobp.2024.07.1209OpenAlex
- 88top 3.1%
MR-Linac On-Line Weekly Adaptive Radiotherapy for High Grade Glioma (HGG): Results from the UNITED Single Arm Phase II Trial
J. Detsky, Annie W. Chan, Daniel Moore-Palhares, John M. Hudson, James Stewart and 10 more
15 citationsdoi:10.1016/j.ijrobp.2024.08.016OpenAlex
- 89top 3.1%
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer
Pier Paolo Avolio, Ronald Kool, Bobby Shayegan, Gautier Marcq, Peter C. Black and 16 more
15 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.ijrobp.2024.08.036OpenAlex
Show abstractHide abstract
PURPOSE: To compare the oncologic outcomes of patients with nonmetastatic muscle-invasive bladder cancer (MIBC) undergoing complete versus incomplete transurethral tumor resection (TURBT) before radiation therapy. METHODS AND MATERIALS: Patients with nonmetastatic MIBC who underwent curative-intent radiation therapy between 2002 and 2018 at 10 Canadian institutions were retrospectively evaluated. Inverse probability of treatment weighting was performed using baseline characteristics. Differences in survival outcomes by complete and incomplete TURBT were analyzed. RESULTS: Of the 757 patients included, 66% (498) had documentation of a complete and 34% (259) an incomplete TURBT. Before adjustment, 121 (47%) and 45 (9%) patients who underwent incomplete and complete TURBT, respectively, were diagnosed with cT3-4 tumor (P <.001). After weight-adjustment, all baseline cohort characteristics were balanced (absolute standardized differences < 0.1). The adjusted median follow-up was 27 months. Adjusted survival analyses showed no significant difference in 5-year overall survival (48% vs…
- 90top 3.2%
Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE
Supriya Chopra, Tjalling Bosse, Nanda Horeweg, Kedar Deodhar, Santosh G. Menon and 17 more
15 citationsOpen access (CC-BY)doi:10.1016/j.ijrobp.2024.07.2316OpenAlex
Show abstractHide abstract
PURPOSE: BIOEMBRACE was designed to study the impact of biomarkers in addition to clinicopathological factors on disease outcomes in patients treated with chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy (BT) for locally advanced cervical cancer in the EMBRACE study. METHODS AND MATERIALS: Between 2018 and 2021, 8 EMBRACE-I sites contributed tumor tissue for the immunohistochemistry of p16, PD-L1, and L1CAM. These biomarkers and clinicopathological factors (International Federation of Gynecology and Obstetrics 2009 stage, nodal status, histology, and necrosis on MRI) were analyzed to predict poor response at BT (high-risk clinical target volume [HR-CTV] ≥ 40 cc) at BT) and 5-year local control, pelvic control, and disease-free survival. Interaction between p16, PD-L1, radiation therapy dose (HR-CTV D90), and disease outcomes was investigated. Univariable and multivariable analyses were performed. RESULTS: Two hundred sixty-four patients were included. The median HR-CTV D90 was 89 Gy (86-95). P-16 positive status, PD-L1 > 1%, and L1CAM ≥ 10% was noted in…
- 91top 3.2%
Enhancing Precision in Cardiac Segmentation for Magnetic Resonance-Guided Radiation Therapy Through Deep Learning
Nicholas Summerfield, Eric D. Morris, Soumyanil Banerjee, Qisheng He, Ahmed I. Ghanem and 4 more
15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.05.013OpenAlex
- 92top 3.2%
Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial
Qi Zhang, Shaonan Fan, Xiaohong Xu, Shisuo Du, Guangying Zhu and 10 more
15 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.03.030OpenAlex
Show abstractHide abstract
PURPOSE: The standard treatment schedule for unresectable stage III non-small cell lung cancer (NSCLC) is chemotherapy with concurrent radiation therapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiation therapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiation therapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy. METHODS AND MATERIALS: In this randomized, multicenter, nonblinded phase 3 clinical trial, eligible patients were randomised at a 1:1 ratio to either the Hypo-RT group (60 Gy in 20 fractions) or Con-RT group (60 Gy in 30 fractions). All patients received 2 cycles of concurrent platinum-based chemotherapy plus 2 cycles of consolidation therapy. The primary endpoint was 3-year overall survival (OS) in the intention-to-treat population. The secondary endpoints were progression-free survival and treatment-related adverse events. RESULTS: A total…
- 93top 3.3%
Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial
Priyamvada Maitre, Guncha Maheshwari, Joyita Sarkar, Pallavi Singh, Sadhana Kannan and 9 more
15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.03.023OpenAlex
- 94top 3.3%
Outcome After Modern Proton Beam Therapy in Childhood Craniopharyngioma: Results of the Prospective Registry Study KiProReg
Martin Bischoff, Dalia Ahmad Khalil, Sabine Frisch, Claus Maximilian Bäcker, Sarah Peters and 6 more
15 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.03.015OpenAlex
Show abstractHide abstract
Background Craniopharyngiomas (CPs) are rare tumours of the sellar region often leading to significant comorbidities due to their close proximity to critical structures. Aim of this study was to analyse survival outcome and late toxicities after surgery and proton beam therapy (PBT) in childhood CPs. Patients and methods Within the prospective XXXX study (XXXX), data of 74 childhood patients with CP, receiving PBT between 08/2013-06/2022 were eligible. Late toxicities were analysed according to the grading system of CTCAE 4.0. Results : Median follow-up (FU) since first diagnosis was 4.3 years (range, 0.8-14.7). 75.7% of patients received PBT at time of disease progression or recurrence, whereas 24.3% as part of their primary therapy (definitive or adjuvant). Predominantly (85.1%), pencil beam scanning technique was used. Median total dose and initial tumour volume were 5400 cGyRBE (relative biological effectiveness) and 17.64 cm³ (range, 3.07-300.59), respectively. The estimated (±SE) 3-year overall survival, progression-free and cystic failure-free survival rate after PBT were…
- 95top 3.3%
Linear Energy Transfer Measurements and Estimation of Relative Biological Effectiveness in Proton and Helium Ion Beams Using Fluorescent Nuclear Track Detectors
Iván Domingo Muñoz, Daniel García-Calderón, Renato Félix‐Bautista, Lucas Norberto Burigo, Jeppe Brage Christensen and 6 more
15 citationsOpen access (CC-BY-NC)doi:10.1016/j.ijrobp.2024.02.047OpenAlex
Show abstractHide abstract
Purpose To develop a methodology for assessing the linear energy transfer (LET) and relative biological effectiveness (RBE) in clinical proton and helium-ion beams using fluorescent nuclear track detectors (FNTDs). Methods and materials FNTDs were exposed behind solid water to proton and helium- ( 4 He-) ion spread-out Bragg peaks (SOBPs). Detectors were imaged with a confocal microscope, and the LET spectra were derived from the fluorescence intensity. The track- and dose-averaged LET (LET F and LET D , respectively) were calculated from the LET spectra. LET measurements were used as input on RBE-models to estimate the RBE. Human alveolar adenocarcinoma cells (A549) were exposed at the same positions as the FNTDs. The RBE was calculated from the resulting survival curves. All measurements were compared with Monte Carlo simulations. Results For protons, average relative differences between measurements and simulations were 6% and 19% for LET F and LET D , respectively. For helium ions the same differences were 11% for both quantities. The position of the experimental LET spectra…
- 96top 3.4%
NRG Oncology and Particle Therapy Co-Operative Group Patterns of Practice Survey and Consensus Recommendations on Pencil-Beam Scanning Proton Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies
Wei Liu, Hongying Feng, Paige A. Taylor, Minglei Kang, Jiajian Shen and 11 more
15 citationsOpen accessdoi:10.1016/j.ijrobp.2024.01.216OpenAlex
- 97top 3.4%
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial
Sarah E. Baker, Linden Lechner, Mitchell Liu, Jee Suk Chang, Ella Mae Cruz-Lim and 25 more
15 citationsdoi:10.1016/j.ijrobp.2024.01.008OpenAlex
- 98top 3.4%
A Prospective, Phase II Study of 177Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort
Kenneth Wing Merrell, Derek Richard Johnson, Kimberly O. Steinert, Michael W. Ruff, W. Breen and 10 more
14 citationsdoi:10.1016/j.ijrobp.2024.07.003OpenAlex
- 99top 3.5%
Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-Based Autosegmentation in Pencil Beam Scanning Proton Therapy
Hongying Feng, Jie Shan, Carlos Vargas, Sameer R. Keole, Jean-Claude M. Rwigema and 9 more
14 citationsdoi:10.1016/j.ijrobp.2024.09.032OpenAlex
- 100top 3.5%
Experience of Implementing Deep Learning-Based Automatic Contouring in Breast Radiation Therapy Planning: Insights From Over 2000 Cases
Byung Min Lee, Jin Sung Kim, Yongjin Chang, Seo Hee Choi, Jong Won Park and 4 more
14 citationsdoi:10.1016/j.ijrobp.2024.02.041OpenAlex
How to read this list
The cohort is every article, review and book chapter OpenAlex attributes to International Journal of Radiation Oncology*Biology*Physics with publication year 2024, excluding retracted works and paratext such as editorials and errata. The top 100 by citation count are listed; the percentile is the rank divided by the cohort size. 37 of the 100 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.
Other journals, same idea
Work with these 25 papers in Kahubi
- The papers land in your library with their DOIs
- Ask anything across all of them, with citations
- Draft a literature review from the same sources
Free plan, no card. Your files stay private unless you share them.
Reading several of these?
Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.